NCI established the RAS initiative in 2013 to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new …

2025年1月6日 · RAS — an abbreviation for rat sarcoma — is the most commonly mutated oncogene in human cancer. RAS mutations are found in 20% of all cancers and account for an …

There are striking cancer-type-specific mutational profiles of RAS gene isoforms in cancer, suggesting tissue-distinct roles for RAS in driving oncogenesis. For example, there is near …

2024年11月9日 · RAS signaling enhances nutrient flux in cancer by participating in central carbon metabolism and increasing glucose uptake and glycolysis, thereby providing a competitive …

2024年4月8日 · Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS and HRAS …

Genetic analyses found that RAS is one of the most deregulated oncogenes in human cancers. In this review, we summarize the pioneering works which allowed the discovery of RAS …

2021年7月23日 · Therefore, here we fully review RAS mutations in human cancer and especially focus on emerging strategies that have been recently developed for RAS-targeting therapy. …

2025年3月31日 · Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible …

2024年4月16日 · The most promising combinatorial strategies that have been developed to combat RAS-driven cancers typically fall into one of four categories: enhancing RAS pathway …

2025年3月29日 · The process of docking K-Ras gene-associated RALGDS inhibitor pancreatic cancer-targeted drugs involves predicting the binding affinity, finding of allosteric site of the …